ImClone Systems Inc (formerly IMCL)

[biophud]

I’m still trying to digest all of the recent news. I’m confused by the recent talk of splitting up IMCL. The questions that I have are the following:

1. Does splitting IMCL mean splitting Erbitux from 11F8 with BMY buying Erbitux and IMCL developing 11F8 and the rest of the pipeline?-->Negatives potential antagonistic situation between IMCL and BMY; up-side for IMCL if 11F8 can out compete Erbitux.

or

2. Does Splitting IMCL mean BMY buying both Erbitux and 11F8 with the remainder of IMCL being spun off as a new equity?-->Advantage preserves the anti-EGFR franchise under one entity with both cash and equity to IMCL shareholders (granted such an equity would have more intrinsic risk once the only approved drug has been divested).

In my opinion it does not make sense to split Erbitux from 11F8--The same company (or companies) that develop Erbitux should develop the second-generation molecule (IMO). I would think that having established sales and distribution channels with Erbitux would facilitate introduction of the second-generation molecule.

We will see what happens.

Comments appreciated,

biophud